manufactur cell china initi buy rate
initi coverag cellular biomedicin
group buy rate price target
develop current manufactur practic cgmp
grade cell therapi manufactur capabl nearli decad key
partnership ge rate thermo fisher buy
pt analyst sung ji nam squar feet
manufactur space across four facil china major locat
pharma valley shanghai squar feet intern
cgmp-compliant ge relationship help enabl
develop integr semi-autom close process
manufactur raw materi plasmid viral vector finish
product high-throughput commerci manufactur scale -- thu lead
meaning lower cog maintain equival qualiti rel
larg manufactur space
cbmg manufactur capabl valid collabor
novarti nv rate septemb enter licens
collabor agreement novarti gave exclus right
manufactur kymriah china autolog car-t therapi approv
sever hematolog malign number countri includ
 japan detail econom agreement
disclos entitl receiv single-digit royalti payment net
sale kymriah china assum well mark-up
manufactur cost assum estim cbmg relationship
novarti account shi compani current enterpris valu
demograph healthcar deliveri regulatori environ china
becom increasingli favor multi-national domest
biopharma player sever on-going major demograph trend
china continu catch attent multi-national biotech firm
includ age popul grow middl class rapid
urban popul addit meaning biopharma regulatori
reimburs qualiti reform led favor environ
intern domest player despit appear escal
tension china
valuat compani enterpris valu suggest get much
credit follow proprietari pipelin could launch
china potenti independ -base partner launch cell
therapi clinic asset opportun pursu similar
relationship multi-national pharma compani look launch china
remaind pipelin product candid target bcma
potenti partner -base compani launch capabl
idc btig estim compani document
million except per share amount
develop cgmp grade cell therapi manufactur capabl nearli decad
squar feet manufactur space across four facil china compani manufactur capabl
valid collabor novarti compani gain right exclus
manufactur kymriah china addit develop pipelin wholli own immuno-oncolog
product leverag number therapeut modal includ number product candid either clinic
expect clinic within next month
initi registr trial kymriah china end approv
cfda end
ind filing/accept bcma nmpa initi safeti
efficaci data iit phase trial china r/r mm expect
initi safeti efficaci data on-going phase trial
china patient r/r dlbcl r/r sll/cll
initi clinic trial china compani bi-
specif car-t product candid prior
initi clinic trial dose first patient china either tcr-t
cell product candid and/or til product candid expect late
allojoin compani plan initi pivot phase clinic trial china
treatment koa expect
base case model assum kymriah receiv approv china r/r
r/r nhl assum entitl royalti payment equal
total treatment revenu mark-up manufactur cost
assum receiv approv china
kymriah assum probabl drug receiv
approv china upsid scenario compar base case
similarli assum chanc
receiv approv upsid scenario compar base case
base assumpt upsid scenario arriv pt
downsid scenario remov valu compani platform
estim valu wholli own product candid current
assum kymriah chanc receiv approv china
downsid scenario compar base case
base assumpt downsid scenario arriv pt
clinical-stag biopharmaceut
compani broad pipelin
therapi tcr-t cell therapi
primari target market china
own gmp facilti
develop signific
licens collabor
agreement novarti
manufactur suppli fda-
product kymriah china
candid anti-
bcma car-t cell therapi
treatment multipl myeloma
provid brief background found made ten year
invest develop large-scal cell therapi contract manufactur organ capac china
also invest wholly-own cell therapi pipelin includ candid regen medicin
compani began develop immuno-oncolog compani began develop
headquart new york facil gaithersburg md compani biomanufactur capac
predominantli locat china amass squar foot capac across four locat china
major locat pharma valley shanghai follow locat beij wuxi space
squar feet built intern cgmp manufactur iso standard
initi coverag buy rate price target invest thesi follow
large-scal manufactur facil incorpor integr process autom close system
provid global advantag sinc build first facil focus build manufactur
capabl incorpor autom process optim ultim effort allow
compani reduc manufactur cost also adher gmp-grade qualiti standard cell therapi
manufactur highli complex given mani cell therapi candid commerci
late stage trial origin academia transit asset commerci compani proven
difficult term meet clinically-regul specif well abil scale
sever well-public exampl larg cell therapi compani run manufactur challeng
whether meet cell viabil stringent clinical-grad releas criteria ramp product
capabl scale vein-to-vein time cost per treatment market abl bear
compani oper integr manufactur gmp-grade raw materi plasmid viral vector car-t
cell chemistri well comprehens manufactur autolog cell therapi includ collect
manufactur process storag capabl importantli compani also develop key
manufactur partnership thermo fisher believ contribut
compani cost advantag disclos manufactur cost car-t therapi rel
base compani howev believ compani abl manufactur autolog car-t around
discount
agreement novarti manufactur kymriah china provid valid cbmg clinic
capabl previous develop car-t product receiv ind
accept b-cell nhl chines fda known nation medic product
administr nmpa septemb sign agreement novarti act compani
exclus cell therapi china kymriah although novarti use differ provid manufactur
lentiviru first phase given manufactur input kymriah line compani
registr part agreement ceas develop product candid
detail around specif econom novarti arrang somewhat opaqu know
receiv escal single-digit royalti net sale subject undisclos annual cap well
mark-up cbmg intern manufactur cost addit novarti took equiti stake compani
valuat share worth roughli million time novarti receiv ind accept
nmpa kymriah august clock tick novarti abl launch kymriah
sever potenti avenu nmpa could take term data requir approv
kymriah china efficaci kymriah well-establish relaps refractori r/r patient
drug approv sever countri includ japan expect nmpa
requir full-blown clinic studi china howev assum like agenc requir
form domest confirmatori studi go detail around assumpt behind valuat
kymriah agreement howev estim base case novarti agreement repres
million enterpris valu shi total current enterpris valu million
biopharma regulatori environ increasingli favor domest player chines
govern indic want increas domest biotechnolog sector countri economi
effort chines govern encourag in-hous innov includ abil use
hospital-bas trial proof-of-concept resourc nmpa drive faster approv well sever
reform effort led burgeon domest biolog market especi car-t therapi
well note chines popul undergo sever major demograph trend
continu catch attent multi-national biotech firm includ age popul grow
middl class rapid urban popul meaning biopharma regulatori reimburs
qualiti reform facilit faster time approv non-domest drug
compani wholli own immuno-oncolog pipelin provid upsid believ incorpor
stock build robust pipelin proprietari cell therapi asset includ sever
singl antigen direct car-t candid bcma multipl myeloma relaps nhl
aml engin tcr cell program afp hepatocellular carcinoma til product candid
initi investigator-bas first-in-human trial china anti-bcma car-t product candid
januari proceed dose escal second quarter start enrol patient
second cohort manag indic present clinic data fourth quarter
submit pre-ind applic nmpa compani leverag chines
investigator-initi trial iit process china intend pursu develop china also intend bring
clinic asset market model two compani candid multipl myeloma
dlbcl sll/cll collect account slightli less roughli price
stock thought valuat
cbmg stock price nearli high reach septemb
interestingli compani stock price peak right announc strateg licens collabor
agreement novarti month follow announc cbmg stock price fell slightli less
although initi rebound compani current stock price much closer price end octob
high addit escal tension china recent short nois around chines
biotech compani spite entir model may increas skittish around invest
chines biotech
suspect initi sell-off driven view compani given away key therapeut asset
intent becom iron valu cell therapi manufactur expertis capac scale
much appreci upsid potenti could greater compani elect
develop wholli own car-t product candid china view novarti partnership meaning
posit clearli valid compani cell therapi manufactur capabl de-risk
commerci cbmg first initi car-t product
base compani current enterpris valu million calcul novarti deal repres almost
compani enterpris valu suggest get much credit follow proprietari
pipelin compani could launch china potenti independ -base partner launch cell
therapi clinic asset la legend biotech genscript hkg janssen pharmaceut part johnson
johnson rate opportun pursu similar relationship multi-national pharma compani look
launch remaind pipelin bcma potenti partner -base
compani launch capabl
initi patient recruit china phase clinic trial anti-bcma car-t product candid c-
relapsed/refractori r/r multipl myeloma mm well phase investigator-initi clinic trial
car-t product candid target treat relaps diffus larg b-cell lymphoma dlbcl
small b-cell lymphoma sll/cll patient two product candid includ within valuat model assum
third-lin china-bas launch collect add approxim million estim enterpris valu
conserv elect exclud remaind compani wholli own immuno-oncolog pipelin well
allojoin product candid knee osteoarthr koa
final attempt give credit valu platform account manag experi meaning
invest cell therapi manufactur capac pipelin preclin product candid
explicitli consid valuat model order estim valu cbmg platform reli averag
chang enterpris valu recogn set compar compani compani success commerci
platform therapeut case acquir approv set compar compani includ alnylam
rate avexi part novarti bluebird bio rate ioni rate juno part
celgen celg neutral analyst thoma shrader kite part gilead rate multipli
averag chang enterpris valu set compar compani cbmg averag enterpris valu
trail twelv month period determin net present valu approv estim expens attribut
specif product candid expens consist unalloc research develop expens calcul
estim compani total research develop expens year less amount research
develop expens attribut specif product candid total sell gener administr expens
total approxim roughli price target attribut cbmg platform
sum arriv base case price target repres upsid approxim base close
price septemb
term potenti risk highlight follow
gener concern around invest chines biotech companies/compl corpor structur entir
unrel cbmg busi event recent short report issu beigen bgne rate dual
list hong kong exchang well rogu chines investig jianku use crispr
edit twin embryo may neg impact investor confid invest chines biotech compani
compani corpor structur also somewhat complic structur use somewhat controversi
commonli use variabl interest entiti wholli foreign-own enterpris wfoe corpor framework
wfoe/vi approach common structur chines compani oper industri chines govern
deem sensit consequ restrict prohibit foreign invest technolog media telecom medicin
mine educ roughli chines compani list employ gener wfoe/vi structur
includ alibaba baba rate jd com jd rate note cbmg ceo toni bizuo lui previous serv
vice-president alibaba group respons alibaba oversea invest previous cfo hichina
subsidiari alibaba
figur outlin cbmg corpor structur wfoe own own
right shanghai variou contract shanghai conduct compani effort technic
support technic servic technolog transfer conduct clinic trial activ requir
domest licens peopl republ china prc note roughli half chines firm list
use similar structur thu concern disagr sharehold
wfoe whatev reason model would recogn chines govern sharehold
shanghai mr chen mingzh mr lu junfeng split
probability-weight npv million probability-weight npv per shareprobability-weight npv million probability-weight npv per shareprobability-weight npv million probability-weight npv per sharekymriahal dlbcl- less upsid casetot npv pipelinenpv platformtot enterpris valuetot market capitalizationproduct candidatetarget indic downsid casebas case
although prc offici support wfoe/vi structur taken action preclud structur
fairli well entrench prc taken effort implement econom reform measur includ
reduct state ownership product asset said possibl prc may opt chang
toler wfoe/vic time take effort reduc foreign invest chines asset especi given
escal /china tension
figur ownership activ investor type previou month posit
exposur chines tariff hold compani incorpor thu subject chines tariff around
import good china predominantli includ life scienc instrument reagent discuss
detail strateg partnership thermo fisher scientif
establish joint facil compani shanghai facil ge relationship exposur
instrument purchas howev cbmg partnership implement healthcar flexfactori platform
establish januari thu underli capit invest subsequ equip transfer
still unknown around kymriah launch nmpa accept novartiss ind kymriah china
drug approv sever countri still exactli clear registr data agenc requir
long take novarti gener data taken conserv approach time howev delay
chines launch would obvious impact cbmg abil gener revenu product
signific intern domest competit fosun kite biotechnolog jv establish shanghai fosun
pharmaceut group kite pharma april fosun kite obtain ind clearanc nmpa china
august treat patient process carri registr trial china fosun
squar meter squar feet dedic commerci product car-t includ facil
locat tianci intern biolog industri park south zhangjiang scientif citi pharmaceut
share platform call kechuang dream factori facil expect complet end articl
discuss visit fosunkit manag team manufactur plant june includ pictur
current state construct found
china pharmaceut share platform set zhangjiang
western big pharma biotech compani cancer immun cell therapi space made inroad china
partner local compani exampl april seattle-bas juno inc celgen start new
compani wuxi apptec china name jw biotechnolog shanghai co ltd leverag juno car-t tcr
technolog togeth wuxi apptec manufactur platform local expertis develop novel cell-bas
immunotherapi patient hematolog solid organ cancer subsidiari janssen also paid million
china-bas legend world-wide licens
also meaning innov china around car-t develop domest chines compani
estim roughli car-trial oncolog unknown statu stay tune front
signific experi advanc cell therapi manufactur base
key partnership thermo fisher
manufactur deliveri cell therapi involv complex integr process includ harvest cell
patient cell isol activ viral vector transduct gmp grade purif mani commerci product
product candid origin process develop academia thu transit scalabl reproduc
method wide discuss challeng industri
figur schemat autolog cell therapi manufactur process
iyer et al industri autolog adopt immunotherapi manufactur advanc challeng frontier frontier
busi cell therapi manufactur sinc open first facil use semi-
autom fulli close system intern manufactur raw materi proprietari cell therapi candid
facilit cost reduct compani develop built sever chines gmp iso certifi cell
viral manufactur facil across china aggreg squar feet gmp-grade manufactur
capac major hous shanghai facil total squar feet capac three
compani facil design built gmo standard meet intern standard beij shanghai
wuxi final compani current assess feasibl expand manufactur space new site
china
provid timelin cbmg manufactur capabl
compani establish facil design built china manufactur practic gmp
standard wuxi china
compani establish fda gmp standard protocol-compli manufactur facil shanghai
octob compani open facil design built gmp standard beij
compani open zhangjiang facil shanghai pharma valley squar
feet design built gmp standard dedic advanc cell manufactur includ
clean-room independ product line support clinic batch product commerci scale
manufactur capac alon could suppli thousand patient car-t therapi thousand koa
patient stem cell therapi per annum
june compani open global research develop center gaithersburg md
case compani space keep process close chest high level
built integr gmo level plasmid viral vector car-t cell chemistri manufactur control process cbmg
focu fulli integr cell therapi compani enabl becom one compani abl
manufactur clinic grade viral vector china cater increas global demand cell therapi
develop patent-protect institution product process allow integr product raw
materi aav lentiviru retroviru serum serum-fre cultur plasmid vector construct well
cell manufactur bank distribut
figur cell therapi manufactur process result vein-to-vein time day
form key partnership thermo fisher scientif effort reduc cost
improv speed manufactur first compani instal ge healthcar flexfactori cell therapi
close semi-autom system manufactur bioengin cell addit provid
process develop servic conjunct centr commerci regen medicin
ccrm not-for-profit organ base ontario canada focus develop commerci cell
gene therapi ge healthcar ccrm establish centr advanc therapeut cell catct
industri cell manufactur acceler effort compani work cell gene therapi entiti
establish joint cell therapi laboratori within cbmg shanghai facil team work togeth develop
robust process develop effort includ integr autom integr workflow aggreg
last publish number ge resourc pool compris scientist engin expertis advanc
addit form strateg partnership thermo fisher build joint cell therapi technolog
innov applic center cbmg facil shanghai combin thermo biopharma manufactur
qualiti control process cbmg vertic integr cell therapi manufactur system effort lower
cost increas batch stabil reduc variabl institution manufactur process
figur entranc cbmg joint manufactur center
lastli compani made key hire support manufactur effort includ dr helen zhang cbmg svp
technolog manufactur dr zhang decad experi cgmp establish manag well
around develop large-scal manufactur clinic grade cell gene therapi product develop fda standard
previous dr zhang work stem cell cell gene therapi research harvard medic school associ
director cgmp lab oper harvard gene therapi initi
compani disclos cost per dose howev suspect compani current cost per dose least
compani space similarli believ manufactur time could low day versu
standard day report compani space
cbmg manufactur capabl valid collabor novarti
manufactur kymriah china
discuss detail also develop cell therapi pipelin includ regen
medicin immune-oncolog product candid compani ind applic accept chines fda
known nation medic product administr nmpa proprietari autolog car-
patient nhl late septemb enter agreement novarti manufactur
suppli kymriah china term econom minim detail disclos howev base
know believ potenti valu compani repres major cbmg enterpris valu leav upsid
compani wholli own pipelin total cbmg novarti relationship account roughli million
enterpris valu slightli per share base case model repres approxim
compani disclos much term detail know follow use valu potenti
novarti took stake compani agre suspend develop proprietari
also develop intern cell therapi pipelin discuss detail novarti
first right negoti cbmg car-t candid
receiv escal singl digit percentag royalti kymriah net sale china assum
royalti certain cap sale dlbcl pediatr cap undisclos
respons cost bi-direct technolog transfer two compani
also oblig assist novarti develop kymriah china compani respons
certain percentag total develop cost develop kymriah china indic
dlbcl pediatr
addit treatment revenu make assumpt estim amount net profit compani
gener manufactur compon agreement novarti assum earn
mark-up manufactur product
latest earn call cbmg manag team indic track complet novarti tech
transfer kymriah
august novarti ind applic china kymriah accept drug evalu center
state food drug administr given favor regulatori environ china base fact
kymriah obtain approv japan base model assum probabl
kymriah receiv approv cfda treatment third-lin r/r third-lin r/r nhl patient
less clear pathway novarti potenti gilead yescarta alreadi obtain ind
approv take china illustr figur recent reform chines drug approv process
provid multipl pathway non-domest compani obtain approv china depend upon level
unmet need level clinic evid fastest path requir drug approv japan meet
high unmet need enough asian patient data demonstr equival safeti altern
requir sort bridg studi demonstr equival efficaci asian patient believ
assum option figur like model much longer timelin closer option wherebi
novarti receiv approv kymriah china would repres roughli month sinc approv
conserv side base timelin outlin
figur acceler drug approv pathway china
reward regulatori chang launch innov biopharma china
market opportun kymriah china term market opportun china use mortal proxi
third-lin patient reduc number address patient account fact patient
abl undergo car-t cell therapi includ gradual ramp reimburs coverag first year
approv assum market pure self-pay yield higher asp time assum increas insur
coverag well increas competit yield price compress
figur btig estim kymriah address market treat patient
seer cancer databas btig estim
figur kymriah pre-tax free cash flow compon
along chines govern effort facilit approv new drug
combin favor demograph trend point-of servic dynam result
market amen cell therapi
chines govern indic want increas domest biotechnolog sector compani
economi
demograph trend point-of-care-dynam well note chines popul undergo sever
major demograph trend caught attent multi-national biotech firm includ age popul
grow middl class rapid urban popul
figur much like china experienc meaning age popul massiv urban
key driver healthcar demand
sourc china offic nation work commiss age censu bureau japan nation institut popul social
figur chines middl class continu grow proport total popul top ten urban
cluster expect account urban chart show urban popul total
next page exampl comment novarti made around effort expand china mani other
made similar comment
figur novarti comment around effort expand china
novarti file transcript
earningsin respons question around novarti elect partner manufactur kymriah china need manufactuirng china base china law also expect abl assist compani gain access patient popul china think seen last month expand footprint cell therapi manufactur around world think show commit provid access import medicin around earn partnership china think look much partnership manufactur us also work us gain access expect type profit-shar earn kisquli kymriah slower startsbut feel confid given manufactur expans global drive kymriah growth well earn look last coupl year increas invest china sort think industry-lead nrdl list last year transit portfolio older medicin conclud divest end real growth driver posit china invest deploy look forward gather momentum revisit china real growth opportun market space probabl would say earn cell therapi lentiviral-bas therapi big focu next wave innov car-t tri get rapid manufactur high-affin car-t bi-specif car-t next wave technolog say interest see rapid manufactur evolv think potenti truli transform overal approach earn china fda becom realli world-lead term polici allow intern studi done china directli rapidli approv medicin regular reimburs environ predict reimburs environ strategi pivot new launch paul susann organ focus drive new launch enabl us doubl china busi hope ocm five earn china gener focus much launch medicin focus move histor establish medicin busi given number recent approv double-digit approv double-digit reimburs entresto well cosentyx strong start new oncolog medicin strong start focu much drive new launch expect due cours tender impact legaci establish medicin busi primarili gleevec valsartan-contain medicin to-dat tender start signific scale specif medicin varieti reason moment signific impact even come expect launch off-set impact four plu seven tender much focu strategi also believ govern right thing shift resourc older medicin focus new innov actual fit novarti strategi quit well recent review china innov landscap think right regulatori regulatori reimburs standpoint import structur reform think go open market one switch support establish brand move move realli tender market think billion get freed take old establish brand allow high qualiti gener enter tender price time china made coupl import reform open market innov one abil pivot clinic trial china directli phase studi china enabl list think drug abil use data outsid china regist medicin four medicin well includ cosentyx allow us get registr much much quickli much streamlin regulatori review process third element reimburs seen realli increas reimburs mention drug list see reimburs environ pick posit look extern ecosystem observ think one lot invest dollar avail sure invest local chines compani gener see focus patent fast follow today look also look class particularli oncolog see larg number compani enter ensur get around relev ip monoclon antibodi obvious rapid develop also cell therapi car-t well lot fast follower-ori see larg cap global biopharmaceut compani look compani partner plug gap portfolio think seen other deal think recent basic take technolog global local compani hold local yet identifi signific fundament scientif innov obvious car-t space one watch close think regulatori standard need go data qualiti need go actual compar data alway clear mani line prior therapi patient realli even patient given diseas challeng think see much activ see real fundament new target discoveri lead novel drug two see someth opportun perhap fast follow add-on adapt data hard sure realli incred think littl thing get resolv period see uptick barrier see look rest world build leadership posit china well emerg market focu china think particularli import opportun us expect china becom second import market compani enemi approv list nation drug reimburs list expect doubl size chines busi extrem well recent launch entresto recent launch cosentyx chines market keep eye china someth paul team realli focus build susannn well respect oncolog portfolio yeah right everi one technolog differ applic clearli radioligand therapi limit oncolog believ cell therapi gene therapi opportun appli broadli part reason invest kymriah build global scale ex vivo cell manufactur lentiviru believ time take long-run view year go therapi rang area requir us take human cell bodi reprogram put back could hematolog could immun diseas could enzym replac therapi rang opportun also consist invest build manufactur footprint mind use manufactur footprint cart cancer could also use lentiviral-bas cell reprogram cell reprogram approach aris futur acquir compani acquir cellforcur plan acquir cellforcur paris-bas biotech capac capabl cell process cut deal china anoth cell process compani great capabl scale work japan cbri institut also great capabl cell program taken togeth build global manufactur footprint mind platform capabl enabl us continu bring technolog allow us reprogram cell hope cure human diseas analyst day
invest reform effort chines govern made concert effort facilit drug develop
approv china detail specif action taken
five-year govern plan includ effort enhanc origin domest
biotechnolog mandat support new technolog strateg new product
application-crit technolog creation biotechnolog innov platform promot
construct biotech innov center strengthen industri biotech via construct
biotechnolog special high-tech park includ build biopharmaceut specialti park bio-
manufactur specialti park output valu billion yuan
made china made china initi introduc china state council
ultim aim initi comprehens upgrad chines manufactur driven
intern innov versu approach emphasi qualiti quantiti plan goal
rais domest content core compon materi eventu
transform china powerhous high-tech high-valu industri robot advanc
aviat new energi vehicl plu biopharmaceut medic technolog
section discuss biopharmaceut high-perform medic equip plan
identifi type medic product technolog china intend develop includ biologic-
base therapeut antibodi drug antibody-drug conjug new structur protein polypeptid drug
new vaccin technolog support individu drug treatment precis medicin
breakthrough technolog induc pluripot stem cell addit plan call increas
domest market share chines compani sever industri includ biotechnolog market share goal
biopharmaceut core componentswhich may encompass biopharmaceut well tradit
pharmaceuticalsi
nmpa f/k/a cfda reform histor major lag drug approv outsid
china approv china year chines equival fda renam
chines fda cfda nmpa undergon major reform effort past year part
reform nmpa implement prioriti review process announc februari approv
time submiss approv month agenc also underw massiv hire exercis
review expect handl drug applic place end final drug
administr law pass august goe effect decemb recent
draft publish april
key chang put place lead favor environ intern compani
garner approv china includ
open first-in-human trial global develop nmpa reform allow multi-national compani
option enabl foreign applic conduct full clinic develop china tandem global
develop effort previous nmpa requir foreign-develop drug must approv anoth
countri proceed nda submiss china mani multi-national pharmaceut compani
spoken opportun china novarti suggest would seek includ china pivot trial go
forward significantli shorten develop timelin foreign-develop drug innov
figur updat classification/definit new drug china
wang alistair davidson overview major reform china regulatori environ juli
figur china increas number new approv decreas drug lag sinc
reward regulatori chang launch innov biopharma china
simplif submiss process chang
approv format shorten approv process year
importantli china also remov need obtain good clinic practic accredit clinic trial
site open potenti investigator-initi trial iit facilit expans number
drug medic devic indic seriou life-threaten condit signific unmet medic
need earli mid-stag clinic data predict clinic benefit nmpa abl grant
condit approv allow earli market china defin risk manag plan commit
complet requir clinic trial base cfda review conclus
clinic trial data protect applic appli clinic trial data protect request along nda
applic provid six-year protect new drug ten-year protect new orphan drug new
pediatr drug three-year protect modifi new orphan drug new pediatr drug ten-year
protect new biolog product protect start date drug approv within protect
period cfda approv drug differ applic
focu qualiti respons concern around drug safeti issu new incorpor heavi legal
penalti addit new alter safeti inspect system one post-approv enforc
drug manufactur distributor subject on-the-fli inspect nmpa frequent basi
nmpa intend expand post-approv inspect forc supervis pharmaceut compani vendor
supplier domest oversea
use cmo also implement nation market author holder mah system allow drug
develop outsourc manufactur respons safeti efficaci qualiti control
develop product use includ conduct post-market studi advers event monitor
blood product narcot psychotrop medicin toxin elig mah system
state council implement pilot mah system select citi provinc see china detail outsourc
manufactur pilot program could benefici exampl intend pursu
relationship futur
compani pipelin wholli own immuno-oncolog product leverag
number therapeut modal underappreci investor
mention previous compani develop pipelin includ regen medicin immuno-
oncolog target car-t til tcr candid cbmg ultim goal use first-mov advantag china
backdrop enhanc regul central govern differenti competit establish
lead posit china cell therapeut market differ focu place compani differ competit
environ western compani respect fund rais clinic trial collabor partnership
market compet
aggreg assign nearli price target roughli compani pipelin take
account two candid current develop china see mani opportun beyond initi candid
includ compani either bring candid market partner multi-national
compani depend data present expect first candid compani present data
anti-bcma car-t product candid r/r mm current iit dose-escal trial china
whether compani receiv ind nmpa iit gener data seen nmpa remain
seen
sever benefit confer domest biotech manufactur includ abil use gcp-compliant
investig initi trial iit requir hospit local approv enabl chines biopharma
manufactur provid proof-of-concept novel drug chines fda nmpa issu non-bind guidelin
cell therapi candid requir compani use nda/ind pathway obtain approv versu abil
pursu registr base data gener iit nmpa also enabl applic propos clinic trial
structur exampl early-stag confirmatori trial base tradit phase structur
figur upcom catalyst wholli own product candid
product candid indicationcatalyst kymriahiniti registr trial china expect end approv cfda treatment r/r r/r nhl patient expect end pre-ind meet schedul nmpa initi safeti efficaci data on-going phase trial china r/r mm expect fourth quarter safeti efficaci data on-going phase trial china r/r dlbcl r/r sll/cll expect bi-specif car-tiniti clinic trial dose first patient china r/r nhl expect prior fourth quarter initi safeti efficaci data trial expect cell product candid initi clinic trial dose first patient china tcr-t cell product candid aim treat r/r expect prior fourth quarter initi safeti efficaci data trial expect product candidateiniti clinic trial dose first patient til product candid aim treat r/r nsclc expect late earli initi safeti efficaci data trial expect end pivot phase clinic trial china treatment koa expect first quarter
base case model calcul price target impli upsid approxim base close
price septemb key assumpt underli base case model describ
appendix back report screenshot valuat model product candid
valuat model assign probabl kymriah receiv approv nmpa
treatment third-lin r/r third-lin r/r nhl patient calcul address popul indic
use mortal proxi third-lin patient reduc number total address patient indic
account fact patient reach third-lin treatment well includ consider
gradual ramp reimburs coverag
calcul total kymriah treatment revenu indic base total address patient market
penetr assum entitl royalti payment equal total treatment revenu addit
treatment revenu make assumpt estim amount net profit compani gener
manufactur compon agreement novarti assum earn mark-up
manufactur product total kymriah account roughli slightli less price target
provid detail around estim address patient treat patient pre-tax cash flow
kymriah compon royalti payment manufactur revenu invest thesi section report
product candid targetind probability-weight npv million probability-weight npv per sharekymriahal less npv platformtot enterpris valuetot npv pipelinetot market capit
estim probabl product receiv approv cfda treatment
third-lin r/r mm patient consist assumpt kymriah use mortal proxi third-lin patient
order come address patient popul reduc number total address patient
indic account fact patient reach third-lin treatment well includ
consider gradual ramp reimburs coverag sinc product wholli own treatment revenu
calcul number total address patient multipli assumpt market penetr total c-
account slightli approxim price target
similarli estim probabl cbmg product receiv approv cfda
treatment treat relaps dlbcl sll/cll patient use mortal proxi third-lin patient
order come address patient popul reduc number total address patient
indic account fact patient reach third-lin treatment well includ
consider gradual ramp reimburs coverag also reduc number address
patient account fact product specif target patient relaps follow treatment anti-
car-t product candid wholli own therefor treatment revenu calcul number total
address patient multipli assumpt market penetr total account bit less
approxim price target
calcul upsid scenario made follow adjust base case assumpt discuss detail
given approv statu kymriah chines govern increas focu bring new
drug market upsid scenario assum kymriah chanc receiv approv china
compar base case
similarli given well-valid natur bcma target car-t cell therapi assum c-
chanc receiv approv china upsid scenario compar
base case
base differ assumpt discuss arriv price target impli upsid
approxim base close price septemb
product candid target indic probability-weight npv million probability-weight npv per sharekymriahal less npv platformtot enterpris valuetot npv pipelinetot market capit
calcul downsid scenario made follow adjust base case assumpt discuss detail
extrem downsid scenario remov valu compani platform estim
valu wholli own product candid current develop
account potenti impact on-going trade war china assum kymriah
chanc receiv approv china downsid scenario compar base case
base differ assumpt discuss arriv price target impli downsid
approxim base close price septemb
product candid target indic probability-weight npv million probability-weight npv per sharekymriahal dlbcl- less npv platformtot enterpris valuetot npv pipelinetot market capit
high level immunotherapi type cancer treatment help individu immun system fight cancer either assist immun system
attack cancer directli stimul immun system gener way immun system often struggl recogn cancer cell
foreign result variou trick tumor cell use evad respons and/or due lack cell specif current two main type immunotherapi
use treat cancer monoclon antibodi immun checkpoint inhibitor
use checkpoint inhibitor shown promis result treat certain cancer howev checkpoint inhibitor caus seriou side effect
peopl use allow immun system attack normal organ bodi addit checkpoint inhibitor provid solut issu
lack necessari cell specif thu patient cell lack necessari specif recogn cancer cell foreign effect
immun checkpoint inhibitor limit order improv specif cell two engin cell therapi approach emerg chimer
antigen receptor -t cell therapi cell receptor tcr -t cell therapi discuss approach detail
addit car-t cell therapi tcr-t cell therapi number compani attempt develop adopt cell therapi leverag tumor-
infiltr lymphocyt til discuss til detail later report high level cell deriv patient immun cell
specif lymphocyt recogn potenti kill patient cancer cell til natur travel penetr exist cancer
tumor immune-suppress environ tumor often limit number activ ultim diminish abil til
effect attack cancer order address issu adopt cell therapi til involv remov patient til tumor expand
til ex vivo infus patient expand til
shown cbmg immuno-oncolog pipelin includ car-t cell therapi tcr-t cell therapi til-bas therapi discuss compon
compani immuno-oncolog pipelin detail
car-t cell therapi form engin cell therapi aim increas cell specif high level process involv isol cell
manipul cell ex vivo express allow manipul cell prolifer infus edit cell patient
two primari approach cell therapi autolog use cell deriv individu patient allogen use engin cell
deriv healthi donor cell
engin artifici receptor direct cell specif antigen present surfac tumor cell effect combin
specif antibodi function cell detail figur first gener compos single-chain fragment scfv deriv
antibodi extend onto surfac engin cell recogn target antigen target bind domain link
transmembran domain hing link scfv target bind domain activ element insid cell activ domain found insid
cell consist two contigu domain respons activ cell bind target cell
autolog car-t cell therapi shown abil drive signific remiss rate among r/r patient particular posit cancer august
fda approv kymriah autolog car-t cell therapi design target treatment patient year age b-cell
precursor acut lymphoblast leukemia refractori relaps least twice decis kymriah becam first gene therapi
product approv
kite/gilead becam second compani receiv approv autolog car-t cell therapi yescarta approv fda octob
similar kymriah yescarta autolog car-t cell therapi fda approv yescarta treatment certain type larg b-cell
lymphoma includ diffus larg b-cell lymphoma dlbcl primari mediastin larg b-cell lymphoma pmbcl high-grad b-cell lymphoma
transform follicular lymphoma fl respond relaps least two kind treatment
anti-bcma car-t product candid multipl myeloma mm
product anti-bcma car-t cell
therapi treatment relapsed/refractori
compani initi patient recruit
china clinic practic
compliant investig initi trial iit c-
wait feedback
nmpa around submit pre-ind meet
approv local hospit institut
review board irb time cost
effici tradit ind rout
ultim goal phase trial
gmp compliant manufactur capabl
produc data allow
advanc pivot trial
figur bcma antitumor activ compar industri lead candid
current preced
constitut approv car-t data packag multipl myeloma howev data celgenes/bluebird bio product candid appear
approv compani anticip first potenti approv product candid treatment relapsed/refractori multipl myeloma
recal autolog car-t product candid target b-cell matur antigen bcma present surfac multipl
myeloma cell thu number clinic trial investig antigen target ligand lewi
antigen bcma consid well-valid target multipl myeloma
expect present initi safeti efficaci data on-going phase trial evalu fourth quarter like
take place decemb orlando florida
figur iit phase trial design relaps resist multipl myeloma
car-t product candid non-hodgkin lymphoma nhl small lymphocyt lymphoma sll chronic
june initi phase trial
china car-t product candid
aim treat r/r diffus larg b-cell lymphoma
dlbcl r/r small b-cell lymphoma patient
sll/cll relaps follow treatment
car-t cell therapi compani
sinc dose first relaps dlbcl patient
figur car-t therapi relaps nhl
kymriah yescarta shown abil
leukemia lymphoma patient howev loss
surfac antigen caus treatment failur
make re-treat
car-t ineffect roughli half patient
leukemia relaps follow direct
therapi antigen escap lymphoma patient figur roughli research tri better understand driver
antigen loss wide understood acquir mutat lead complet loss downregul well modif receptor
car-t longer recogn target tumor also undergo phenotyp switch lineag express thu clearli
opportun addit car-t product attack secondari target aid remiss among patient relaps follow treatment anti-
car-t cbmg car-t product candid take advantag well-character presenc antigen establish
target cancer treatment result believ product candid repres viabl treatment option patient relaps follow
treatment car-t
expect present initi safeti efficaci data on-going phase trial evalu car-t product candid sometim
second third quarter
case car-t cellular therapi tcr-t cellular therapi redirect
cell specifi cellular target done alter cell specif
express specif tcr facilit antigen-recognit
process order creat antigen-specif cell tumor specif tcr
construct transduc cell ex vivo typic use viru
lentiviru car-t therapi abl target surfac marker
cancer cell engin tcr recogn antigen endogen fashion
via recognit epitop tumor specif antigen
display mhc class molecul surfac antigen present cell
although tcr-base therapeut restrict specif hla allel
therefor multipl product may need benefit use engin
tcr approach therapeut target protein
intracellular result tcr abl target wider rang antigen
well specif uniqu mutat occur tumor cell gene
cell therapi approach target variou antigen includ tumor-
associ antigen overli express tumor also
express healthi tissue/cel viral antigen hpv ebv
known associ cancer cancer/testi antigen antigen
restrict normal express male germ cell testi
adult somat tissu shown overexpress
cancer final approach target holi grail target
neoantigen neoantigen aris mutat cancer genom lead
alter protein structur antigen express cancer
cell subject central peripher toler
neoantigen share across cancer type major
tumor-specific/pati specif cell therapi effort leverag neoantigen
target concept success highli mutat cancer challeng
target neoantigen abil identifi subsequ
develop target therapeut patient specif neoantigen profil
figur comparison car-t tcr-t therapi
given earli stage natur cbmg tcr-t cell therapi product difficulti associ target solid tumor valuat model
includ consider compani tcr-t cell therapi pipelin februari obtain royalty-bear exclus licens patent
own augusta univers around afp-target engin tcr hepatocellular carcinoma compani expect initi clinic trial
dose first patient china tcr-t cell product candid aim treat r/r hepatocellular carcinoma prior fourth quarter
expect see initi safeti efficaci data trial sometim
car-t cell therapi receiv bulk investor attent follow approv yescarta kymriah predat tumor-infiltr
lymphocyt til therapi til therapi cell harvest directli patient tumor oppos type adopt cell therapi take
circul cell patient blood simultan dna isol patient tumor sequenc find mutat specif cancer
neoantigen determin specif neoantigen present patient cancer til recogn neoantigen select
expand larg number laboratori infus back patient activ attack cancer cell leav
healthi cell alon previous discuss cell therapi effort leverag neoantigen target concept success highli mutat cancer
exampl iovanc til therapi melanoma cervic cancer effect remov re-activ tumor-infiltr lymphocyt tumor theori
tumor-infiltr lymphocyt would alreadi condit respond specif neoantigen express tumor therefor til
therapi repres straightforward way target patient specif neoantigen rel tcr-t cell therapi requir develop
target therapeut recogn patient specif neoantigen
enter non-exclus licens agreement nation cancer institut nci octob access patent pursuant
patent compani right world-wide develop manufactur commerci autolog tumor-react lymphocyt adopt
cell therapi product isol til treatment non-smal cell lung stomach esophagu colorect head neck cancer human
notabl steven rosenberg phd chief surgeri nci first publish work show til isol patient metastat
melanoma could expand lab return patient ultim mediat cancer regress opinion nci decis grant
licens also help give us confid compani intern capabl iovanc similar licens along term
develop til therapi unit state consider opportun bring til therapi market china well unit
state given earli stage natur cbmg til product difficulti associ target solid tumor valuat model includ
consider compani til product pipelin howev expect initi clinic trial dose first patient china til
product candid aim treat r/r non-smal cell lung cancer nsclc sometim late earli expect see initi safeti efficaci
data trial sometim end
outsid cancer develop re-join allojoin stem cell treatment knee osteoarthr koa allojoin off-the-shelf allogen
adipos deriv progenitor cell hampc therapi design improv knee function reliev pain
koa clinic trial conduct china decemb stem cell trial polici
januari launch allogen koa phase trial china evalu safeti efficaci allojoin patient treatment complet
august interim three month safeti data trial china announc decemb interim analysi trial preliminarili
demonstr safeti toler profil allojoin three dose test seriou advers event observ posit phase
data present march demonstr good safeti earli efficaci slow cartilag deterior
januari compani approv conduct pivot phase ii clinic trial china allojoin product candid first drug
grant ind new chines regul enact rule cell therapi treat drug septemb
announc held meet investig shanghai launch phase ii clinic trial allojoin compani plan recruit patient
grade ii-iii koa phase ii trial six lead hospit china
includ consider allojoin valuat model note koa market repres signific opportun
million patient china alon thu could see upsid allojoin move forward
mr liu join independ director chairman audit committe march appoint chief offic
compani januari chief execut offic februari prior time mr liu serv corpor vice presid alibaba group
respons alibaba oversea invest time alibaba held variou posit includ gener manag
global e-commerc platform chief offic hichina subsidiari alibaba lead internet infrastructur servic provid mr liu also
spent year posit corpor account director made key leader corpor financ depart
addit serv microsoft corpor account director develop microsoft china invest strategi corpor strateg plan
process mr liu obtain washington state certif
dr zhang bring year research experi relat tissu cellular molecular biolog graduat medic school
spent year work pathologist clinic instruct capac began cell gene studi max delbrck
center molecular medicin berlin germani becam first asian research scientist award best research scientist
fellowship went work year stem cell research gene/cel therapi research harvard medic school notabl associ
director cgmp laboratori oper harvard gene therapi initi dr zhang success led team provid clinic grade cell therapi
gene therapi product clinic trial organ harvard dana farber cancer institut gnthon muscular dystrophi
associ year experi cgmp establish manag well large-scal manufactur clinic grade cell gene
therapi product meet fda standard consid dr zhang one compani import asset critic success introduct
kymriah chines market place
dr yao lead cbmg overal scientif research program area immuno-oncolog inflammatory/autoimmun diseas bring signific
expertis clinic biomark discoveri develop strategi person medicin nearli year life scienc industri
academia addit complet postdoctor fellowship john hopkin univers year profession experi
pharmaceut biotechnolog compani includ medimmun wholli own research develop subsidiari astrazeneca abbott
bioresearch center dr yao co-inventor file patent relat tumor classif degen muscl diseas autoimmun diseas
diagnost treatment sixti publish paper translat scienc peer-review journal two publish book subject
inflammatori autoimmun diseas genom biomark frequent invest speaker panelist mani intern confer
biomark person medicin mirna rheumatolog oncolog receiv degre biochemistri fu univers shanghai
china master degre bioinformat boston univers ph molecular biolog biochemistri univers kansa
andrew chan chief legal offic corpor develop secretari
prior current role mr chan serv chief offic februari januari mr chan previous
held variou manag role focus busi oper corpor develop mr chan
vice presid busi oper suppli chain manag mindspe technolog vice presid suppli chain manag
conex system earn degre manag embri riddl aeronaut univers univers mr chan also hold
 degre south texa colleg law
dr dai cardio specialist year clinic practic experi year corpor experi prior join serv
ceo medgen technolog director clinic research china beik stem cell technolog medic director venturepharm group ltd dr
dai publish peer-review scientif paper co-author two book receiv master degre cardiolog henan medic
univers doctor medic scienc degre cardiolog postgradu school hospit pla
year experi biopharmaceut biotechnolog industri dr meng driven two round viral vector therapeut
product develop china previous work gener manag transgen tasli tianjin biopharmaceut co ltd exposur
product develop market sale busi manag domest intern compani dr meng receiv degre
wuhan univers china go obtain ph univers pari vi also complet year research notabl
laboratori inserm curi institut franc
michael humphri md head develop strategi
dr humphri previous held number leadership technic posit novarti china oversight direct manag clinic
develop regulatori affair drug safeti clinic oper across therapi area total year experi clinic research
regulatori affair drug safeti medic affair china prior time novarti china dr humphri serv medic director glaxosmithklin
china/hong kong asia-pacif medic director involv drive initi clinic strategi
execut contribut total product launch china
derrick li head strategi investor relat
mr li join compani head strategi investor relat decemb prior join recent riley fbr
serv manag director healthcar investment-bank group mr li co-found tpp healthcar boutiqu financi advisori firm
special cross-bord transact life scienc compani look find invest partnership opportun china mr li receiv dual
bachelor degre account financ villanova univers
alan list md chair scientif advisori board
current presid ceo moffitt cancer center research institut also hold endow professorship dr list well known
pivot work led develop lenalidomid revlimid approv treatment multipl myeloma myelodysplast
syndrom prior current role dr list execut vice presid physician-in-chief vice deputi physician-in-chief chief
malign hematolog divis moffitt author peer-review articl clinician manual myelodysplast syndrom
earn medic degre univers pennsylvania philadelphia complet intern medicin internship samaritan
medic center phoenix arizona also complet fellowship hematolog medic oncolog vanderbilt univers medic center
recipi honorari doctor institut award around world robert langer also serv member
fda scienc board chairman current david koch institut professor mit one
institut professor mit biomed laboratori institut thought world largest focus tissu engin drug
deliveri system articl written issued/pend patent dr langer cite time scientif
public founded/co-found sever compani langer laboratori mit also incub compani dr langer continu
serv formal inform capac number chemic engin train receiv bachelor degre cornel univers
scd mit
current chief section cellular therapi transplant oncolog divis medic director stem cell laboratori attend physician
children hospit philadelphia chop dr grupp extens experi car-t therapi pediatr play pivot leadership role
relat research addit role chop dr grupp also professor pediatr director cancer immunotherapi program
univers pennsylvania perelman school medicin director center childhood cancer research dr grupp
complet clinic train pediatr pediatr hematology/oncolog boston children hospit dana farber cancer institut harvard medic
school postdoctor research immunolog harvard
michael caligiuri md chair extern advisori board
serv dual capac director ohio state univers comprehens cancer center chief execut offic ohio state jame cancer
hospit solov research institut dr caligiuri draw decad experi design lead clinic studi leukemia lymphoma
chair cbmg extern advisori board addit previous mention role dr caliguri origin public abstract review
articl immunolog leukemia serv on/chair numer scientif board aaci etc also current holder john
maraka nationwid insur enterpris foundat chair cancer research earn degre medicin stanford complet internship
resid intern medicin brigham women hospit harvard medic school fellowship medic oncolog bone marrow
transplant immunolog dana-farb cancer institut harvard medic school
appendix kymriah valuat model thousand
revenu kymriah mortal reach third-lin patient reimburs address market treat patients- discount per total treatment revenu mortal dlbcl reach third-lin patient reimburs address market treat patients- discount per total treatment revenu nhl total treatment revenu treatment revenu total treatment revenu treatment revenu total treatment revenu nhl treatment revenu nhl total treatment revenu manufactur cost revenu total cost good sold- patient treated- treatment cost per mark-up manufactur revenu discount cash flow total revenue- total costs- gross income- effect tax cash flow- discount present valu forecast cash flows- termin valu assum growth total net present value- stage approvalphas phase phase probabl net present value- total probability-weight net present
appendix valuat model thousand
revenu mortal reach third-lin patient reimburs address market treat patients- discount per total treatment revenu good sold total cost good sold- patient treated- treatment cost per research develop total expens unit patient enrol clinic per discount cash flow total revenue- total gross effect tax cash discount present valu forecast cash termin valu assum growth total net present stage approvalphas phase phase phase phase phase probabl net present total probability-weight net present
appendix valuat model thousand
revenu mortal reach third-lin patient reimburs treat patient relaps post address patients- market treat patients- discount per total treatment revenu sll/cll mortal dlbcl reach third-lin patient reimburs treat patient relaps post address patients- market treat patients- discount per total treatment revenu nhl total treatment revenu good sold total cost good sold- patient treated- treatment cost per research develop total expens unit patient enrol clinic per discount cash flow total revenue- total gross effect tax cash discount present valu forecast cash termin valu assum growth total net present stage approvalphas phase phase phase phase phase probabl net present total probability-weight net present
factset btig estim
sale oper expens gener sell research impair long-term total oper oper incom interest incom expens incom expens net incom loss incom tax credit provis net incom weighted-averag share net incom loss per growth metric year-over-year collabor expens gener oper incom loss nanmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incom loss nanmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgrowth metric quarter-over-quart collabor expens gener oper incom loss nanananananmnmnmnmnanmnmnmnmnanananet incom loss nanananananmnmnmnmnanmnmnmnmnananaamanda murphi
btig cover compani mention report
appendix analyst certif import disclosur
